line 24, change "(SEQ ID NO: 20)" to --(SEQ ID NO: 19)line 25, delete "(SEQ ID NO: 21)"; line 33, change "(SEQ ID NO: 22)" to --(SEQ ID NO: 20)line 34, delete "(SEQ ID NO: 23)"; 3 line 14, change "(SEQ ID NO: 24)" to --(SEQ ID NO: 21)-Page 93, line 16, change "(SEQ ID NO: 25)" to --(SEQ ID NO: 22)line 29, change "(SEQ ID NO: 26)" to --(SEQ ID NO: 23)--Page 99, line 31, change "(SEQ ID NO: 27)" to --(SEQ ID NO: 24)-line 33, change "(SEQ ID NO: 28)" to --(SEQ ID NO: 25)-line 35, change "(SEQ ID NO: 29)" to --(SEQ ID NO: 26)--; line 36, change "(SEQ ID NO: 30)" to --(SEQ ID NO: 27)--; Page 100, line 1, change "(SEQ ID NO: 31)" to --(SEQ ID NO: 28)--; and line 3, change "(SEQ ID NO: 32)" to --(SEQ ID NO: 29)--.

IN THE CLAIMS

Please cancel Claims 3, 38, and 39.

Please amend the claims as follows:

- 1. (Twice Amended) An isolated substantially homogeneous human mpl ligand wherein the amino acid sequence of the ligand consists of amino acid residues 1 to X of Fig. 8, where X is selected from the group consisting of residues 153-332.
- 9. (Twice Amended) An isolated substantially homogeneous mpl ligand

  [encoded by a nucleic acid having a sequence that hybridizes under
  stringent conditions to the nucleic acid molecules encoding] consisting
  of residues 1 to X of Fig. 8 where X is residue 153.
  - 32. (Amended) The *mpl* ligand of Claim 1 where X is selected from the group consisting of residues 153-166.